SEC
AEGR

Seven Eight Capital’s Aegerion Pharmaceuticals AEGR Stock Holding History

Seven Eight Capital’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,300
Closed -$43.4K – 745
2014
Q3 		$43.4K Sell
1,300
-3,100
-70% -$96.2K 0.03% 403
2014
Q2 		$141K Buy
+4,400
New +$164K 0.14% 245
2014
Q1 		– Sell
-800
Closed -$57K – 603
2013
Q4 		$57K Buy
+800
New +$61.2K 0.06% 383

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Seven Eight Capital's AEGR Position: Q4 2014 in Review

Seven Eight Capital sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2014, closing a stake of 1,300 shares — an estimated $43.4K sold.

Seven Eight Capital first reported a position in AEGR in Q4 2013 and held it in 3 quarters. The position peaked at $141K in Q2 2014. 95 funds tracked by Wall St. Rank hold AEGR as of Q4 2014.

  • Seven Eight Capital reported no remaining Aegerion Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Seven Eight Capital sold 1,300 Aegerion Pharmaceuticals shares in Q4 2014, an estimated $43.4K.
  • Seven Eight Capital first reported a position in Aegerion Pharmaceuticals in Q4 2013 and held it in 3 quarters.
  • Seven Eight Capital's Aegerion Pharmaceuticals position peaked at $141K in Q2 2014.
  • 95 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2014.

Based on Seven Eight Capital's 13F filing for Q4 2014, filed 13 Feb 2015.